ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Molecular docking and molecular dynamics simulations identified BCR-ABL, which, when constitutively activated, yields uncontrolled proliferation and suppression of apoptosis in chronic myeloid leukemia (CML), as a target for withaferin A and withanone (Wi-N) that warrants further investigations [83].